Abstract
Lenacapavir (LEN), a first-in-class multi-stage HIV capsid inhibitor, is indicated in combination with an optimized background regimen (OBR) for the treatment of HIV-1 in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Historically, this population has had limited treatment options, leading to virologic failure and high risk of AIDS-related mortality. The health outcomes associated with LEN+OBR versus relevant comparators in this population were evaluated previously. This current analysis aimed to assess the cost-effectiveness of LEN+OBR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
